End Price Gouging for Medications Act
SB1753, the “End Price Gouging for Medications Act,” would require the Secretary of Health and Human Services to set annual reference prices for prescription drugs. For most drugs, the reference price would be based on the lowest retail list price among a set of reference countries, including Canada, the United Kingdom, Germany, France, Japan, and others. If pricing data are not available for enough reference countries, the Secretary would set an alternative price using factors such as therapeutic value, patient access, research and development costs, and other relevant considerations.
The bill would cap the retail list price of covered drugs for beneficiaries in major federal health programs, including Medicare, Medicaid, CHIP, TRICARE, the VA, the Federal Employees Health Benefits Program, and Indian Health Service-related programs. It would also require manufacturers to offer drugs at the reference price to uninsured consumers and to people with private coverage, so long as the plan’s payment plus cost-sharing does not exceed the reference price. The bill applies to both brand-name and generic drugs approved under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act.
If enacted, the bill would significantly alter federal drug pricing rules by imposing an international reference-pricing framework on prescription drugs sold through federal health programs and, in practice, on broader drug sales to consumers and private plans. It would create a new enforcement mechanism through civil penalties on manufacturers that fail to comply, with penalty revenues transferred to NIH for drug research and development. The bill would affect Medicare, Medicaid, CHIP, TRICARE, VA health care, FEHBP, and Indian Health Service-related programs, and would likely influence pricing behavior across the pharmaceutical market.
Based on the bill text and its sponsorship, the measure is clearly framed as a consumer-cost and anti-price-gouging proposal, suggesting strong support from sponsors focused on lowering prescription drug costs. There is no recorded committee debate or vote history in the provided materials, so no formal bipartisan or partisan sentiment can be inferred from proceedings. The overall tone of the legislation is assertive and reform-oriented, emphasizing lower prices and broader access to medications.
The main likely point of contention is the use of foreign reference pricing to set U.S. drug prices, which pharmaceutical manufacturers and critics may argue could reduce revenues, discourage innovation, or fail to account for differences in health systems and market conditions. Another potential dispute is the bill’s reach beyond federal programs to uninsured people and those with private coverage, which expands its practical effect well beyond traditional government purchasing. Supporters are likely to emphasize affordability, access, and curbing excessive drug prices, while opponents may focus on regulatory overreach and impacts on research and development incentives.